Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 239

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Immune Checkpoint Inhibitor Toxicity in 2018

Johnson, Douglas B., Chandra, Sunandana, Sosman, Jeffrey A.·2018·JAMA

Abstract

Immunecheckpoint inhibitors(ICIs)aremonoclonalantibodiesthat block inhibitors of T-cell activation and function. The use of ICIs can havebeneficial effects onmore than 14different cancers, andeffects have persisted in some patients for more than 5 years (20%-40%; 5-year survival rate inpatientswithmelanoma) (eTable intheSupplement). ICIsblock cytotoxic T lymphocyte antigen 4 (CTLA-4; ie, ipilimumab), programmed death 1 (PD-1; ie, nivolumab, pembrolizumab), or programmed death ligand 1 (PD-L1; ie, atezolizumab, avelumab, durvalumab).Giventhe increasingrateofprescriptionof ICIs,knowledge oftheiradverseeffects(AEs)is importantforphysiciansinmultipleclinicaldisciplines.ThisJAMAInsightsreviewstheclinicalpresentationand managementof themost commonand severe ICI toxicities that nononcologists are likely to encounter.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2018.13995

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 239

Metadata

Authors
Johnson, D. B., Chandra, S., & Sosman, J. A.
Venue
JAMA
Published
2018-10-23
Volume
320
Issue
16
Pages
1702
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W2895125473
Cited by
239
References
3
FWCI
11.21
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune Checkpoint Inhibitor Toxicity in 2018. https://app.cochat.ai/papers/10.1001/jama.2018.13995
The paper
Johnson, D. B., Chandra, S., & Sosman, J. A. (2018). Immune Checkpoint Inhibitor Toxicity in 2018. JAMA. https://doi.org/10.1001/jama.2018.13995

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.